

Table F.1 Data Items Currently or Previously Collected

Data Item	NAACCR Item Number	Collection Dates	
Summary Stage Documentation	2520-2570 2600	1995 - present	
Tobacco Use	Non - NAACCR 9965 - 9968	2011- 2020	
NAACCR Record Version	50	2003 - present	Current version
Address at Dx City	70	1995 - present	
Address at Dx State	80	1995 - present	
FIPS County Code at DX	90	1995 - present	
Address at Dx Zip Code	100	1995 - present	
Address at Dx-Country	102	2013 - present	
Marital Status at Dx	150	2022 - present	
Race 1	160	1995 - present	
Race 2	161	2001 - present	
Race 3	162	2001 - present	
Race 4	163	2001 - present	
Race 5	164	2001 - present	
Spanish/Hispanic Origin	190	1995 - present	
Sex	220	1995 - present	
Age at Diagnosis	230	1995 - present	
Date of Birth	240	1995 - present	
Date of Birth Flag *	241	2010 - present	
Place of Birth	250	1998 - 2013	
Birthplace-State	252	2013 - present	
Birthplace-Country	254	2013 -present	
Text Usual Occupation	310	2010 - present	
Text Usual Industry	320	2010 - present	
Tobacco Use Smoking Status	344	2022 - present	
Sequence Number Central	380	1995 - present	
Date of Initial Diagnosis	390	1995 - present	
Date of Diagnosis Flag	391	2010 - 2022	
Primary Site	400	1995 - present	
Laterality	410	1995 - present	
ICD-O-2 Morph Prior to 2001	420	1995 - 2000	
Behavior prior to 2001	430	1995 - 2000	
Grade of Tumor	440	1995 - 2017	

Data Item	NAACCR Item Number	Collection Dates	
Grade Path Value	441	2011 - 2013	
Grade Path System	449	2011 - 2013	
Diagnostic Confirmation	490	1995 - present	
Type of Reporting Source	500	1995 - present	
Histologic Type ICD-O-3 2001 and forward	522	2001 - present	
Behavior 2001 and forward	523	2001 - present	
Reporting Facility	540	1995 - present	
NPI Reporting Facility (Derived)	545	2009 - present	Derived
Registry/Accession Number	550	1995 - present	
Sequence Number Hospital	560	1995 - present	
Abstractor Initials	570	1995 - present	
Date of Admission/First Contact	580	1995 - present	
Date of Admission/First Contact Flag *	581	2010 – present	
Class of Case	610	1998 - present	
Primary Payer at DX	630	2007 - present	
RX Hosp—Surg Prim Site 2023	671	2023	
RX Hosp—Scope of Reg LN Sur	672	2022 - present	
RX Hosp—Surg Oth Reg/Dis	674	2022 - present	
Date of Reg LN Dissection Flag	683	2022	
RX Hosp--Chemo	700	2022 - present	
RX Hosp--Hormone	710	2022 - present	
RX Hosp—BRM (Immunotherapy)	720	2022 - present	
RX Hosp--Other	730	2022 - present	
Tumor Size Clinical	752	2022 - present	
Tumor Size Pathologic	754	2022 - present	
Tumor Size Summary	756	2016 - present	
Summary Stage 2000 for appropriate years	759	2001 – 2004, 2014-2017	
Summary Stage 1977 for appropriate years	760	1995 - 2000	
Summary Stage 2018	764	2018 - present	
EOD Primary Tumor	772	2022 - present	
EOD Regional Nodes	774	2022 - present	
EOD Metastases	776	2022 - present	
Tumor Size Prior to 2004	780	1998 – 2003	
Regional Nodes Positive	820	1998 - present	
Regional Nodes Examined	830	1998 - present	
Date of Sentinal Lymph Node Biopsy	832	2022 - present	
Date of Sentinal Lymph Node Biopsy Flag	833	2022	

Data Item	NAACCR Item Number	Collection Dates	
Sentinal Lymph Nodes Examined	834	2022 - present	
Sentinal Lymph Nodes Positive	835	2022 - present	
TNM Pathologic T	880	2015 – 2017	
TNM Pathologic N	890	2015 - 2017	
TNM Pathologic M	900	2015 - 2017	
TNM Pathologic Stage Group	910	2015 - 2017	
TNM Pathologic Stage (Prefix/Suffix) Descriptor	920	2015 – 2017	
TNM Clinical T	940	2015 – 2017	
TNM Clinical N	950	2015 – 2017	
TNM Clinical M	960	2015 – 2017	
TNM Clinical Stage Group	970	2015 - 2017	
TNM Clinical Stage (Prefix/Suffix) Descriptor	980	2015 - 2017	
AJCC ID	995	2018 - present	Derived
AJCC TNM Clin T	1001	2018 - present	CoC
AJCC TNM Clin N	1002	2018 – present	CoC
AJCC TNM Clin M	1003	2018- present	CoC
AJCC TNM Clin Stage Group	1004	2018 – present	CoC
AJCC TNM Path T	1011	2018 – present	CoC
AJCC TNM Path N	1012	2018- present	CoC
AJCC TNM Path M	1013	2018 – present	CoC
AJCC TNM Path Stage Group	1014	2018- present	CoC
AJCC TNM Post Therapy Path (yc) T	1021	2021 - present	CoC
AJCC TNM Post Therapy Path (yc) N	1022	2021 - present	CoC
AJCC TNM Post Therapy Path (yc) M	1023	2021 - present	CoC
AJCC TNM Post Therapy Path Stage Group	1024	2021 - present	CoC
AJCC TNM Clin T Suffix	1031	2021 - present	CoC
AJCC TNM Path T Suffix	1032	2021- present	CoC
AJCC TNM Post Therapy Path (yc) T Suffix	1033	2021 - present	CoC
AJCC TNM Clin N Suffix	1034	2021- present	CoC
AJCC TNM Path N Suffix	1035	2021- present	CoC
AJCC TNM Post Therapy Path (yc) N Suffix	1036	2021 –present	CoC
AJCC Edition Number	1060	2015 - present	
AJCC TNM Post Therapy Clin (yc) T	1062	2021- present	CoC
AJCC TNM Post Therapy Clin (yc) T Suffix	1063	2021- present	CoC
AJCC TNM Post Therapy Clin (yc) N	1064	2021- present	CoC
AJCC TNM Post Therapy Clin (yc) N Suffix	1065	2021- present	CoC
AJCC TNM Post Therapy Clin (yc) M	1066	2021- present	CoC

Data Item	NAACCR Item Number	Collection Dates	
Grade Post Therapy Clinical (yc)	1068	2021- present	
Mets at Diagnosis-Bone	1112	2022 - present	
Mets at Diagnosis-Brain	1113	2022 - present	
Mets at Diagnosis – Distant LNs	1114	2022 - present	
Mets at Diagnosis – Liver	1115	2022 - present	
Mets at Diagnosis-Lung	1116	2022 - present	
Mets at Diagnosis-Other	1117	2022 - present	
Lymphovascular Invasion (testis and penis only)	1182	2011 - present	
RX Date Surgery	1200	1995 - present	
RX Date Surgery Flag	1201	2010 - 2021	
Rx Date Radiation	1210	1995 - present	
RX Date Radiation Flag	1211	2010 - 2021	
Date Chemotherapy Started	1220	2010 - present	
RX Date Chemotherapy Flag	1221	2010 - 2021	
Date Hormone Therapy Started	1230	2010 - present	
RX Date Hormone Flag	1231	2010 - 2021	
Date Immunotherapy Started	1240	2010 - present	
RX Date Immunotherapy Flag	1241	2010 - 2021	
Date other Treatment Started	1250	1995 - present	
RX Date Other Flag	1251	2010 - 2021	
Date of Initial Treatment	1260	2010 - present	
Date of Initial Treatment Flag	1261	2010 - present	
RX - Summary Treatment Status	1285	2010 - present	
Rx Summ-Surg Primary Site	1290	1995 - 2022	
RX Summ—Surg Prim Site 2023	1291	2023	
RX Summary - Scope of Reg LN Surgery	1292	2001 - present	
RX Summary - Surgery Other/Dist RX Code	1294	1998 - present	
RX Summary - Reg LN Examined	1296	2001 - 2005	
Surgical Margins of Primary Site	1320	2022 - present	
Reason for No Surgery	1340	1998 - 2002 2006 - present	
RX Summary - Radiation	1360	1998 - 2002 2012 - 2017	
RX Summary - Surgery/Radiation Sequence	1380	2004 - present	
Chemotherapy Code	1390	1995 - present	
Hormone Code	1400	1995 - present	
Immunotherapy Code	1410	1995 - present	
Other Treatment Code	1420	1995 - present	

Data Item	NAACCR Item Number	Collection Dates	
Reason for no Radiation	1430	1998 - 2002 2011 - present	
Reason for no Chemotherapy	1440	1998 - 2002	
Reason for no Hormone	1450	1998 - 2002	
Phase I Dose per Fraction	1501	2022 - present	
Phase I Radiation External Beam Planning Tech	1502	2022 - present	CoC
Phase I Number of Fractions	1503	2022 - present	
Phase I Radiation Primary Treatment Volume	1504	2022 - present	
Phase I Radiation to Draining Lymph Nodes	1505	2022 - present	
Phase I Radiation Treatment Modality	1506	2018 - present	
Phase I Total Dose	1507	2022 - present	
Phase II Dose per Fraction	1511	2022 - present	
Phase II Radiation External Beam Planning Tech	1512	2022 - present	CoC
Phase II Number of Fractions	1513	2022 - present	
Phase II Radiation Primary Treatment Volume	1514	2022 - present	
Phase II Radiation to Draining Lymph Nodes	1515	2022 - present	
Phase II Radiation Treatment Modality	1516	2022 - present	
Phase II Total Dose	1517	2022 - present	
Phase III Dose per Fraction	1521	2022 - present	
Phase III Radiation External Beam Planning Tech	1522	2022 - present	CoC
Phase III Number of Fractions	1523	2022 - present	
Phase III Radiation Primary Treatment Volume	1524	2022 - present	
Phase III Radiation to Draining Lymph Nodes	1525	2022 - present	
Phase III Radiation Treatment Modality	1526	2022 - present	
Phase III Total Dose	1527	2022 - present	
Radiation Treatment Discontinued Early	1531	2022 - present	
Number of Phases of Rad Treatment to this Volume	1532	2022 - present	
Total Dose	1533	2022 - present	
Radiation Regional RX Modality Code	1570	2003 - 2017	
Neoadjuvant Therapy	1632	2022 - present	
Neoadjuvant Therapy-Clinical Response	1633	2022 - present	
Neoadjuvant Therapy-Treatment Effect	1634	2022 - present	
RX Summary - Systemic/Surgery Sequence	1639	2006 - present	
Date of Last Followup or Death	1750	1995 - present	
Date of Last Followup or Death Flag	1751	2010 - 2021	

Data Item	NAACCR Item Number	Collection Dates	
Vital Status	1760	1998 - present	
Cancer Status	1770	2022 - present	
Date of Last Cancer(Tumor) Status	1772	2022 - present	
Date of Last Cancer(Tumor) Status Flag	1773	2022	
Follow Up Source (Derived)	1790	2009 - present	Derived
Current Address City	1810	2022 - present	
Current Address – State	1820	2022 - present	
Current Address -Zip Code	1830	2022 - present	
Addr Current--Country	1832	2022 - present	
Recurrence Date--1st	1860	2022 - present	CoC
Recurrence Type--1s	1880	2022 - present	CoC
Underlying Cause of Death	1910	2022 - present	Linkage
Place of Death-State	1942	2013 - present	
Place of Death-Country	1944	2013 - present	
Date Abstracted	2090	1995 - present	
CoC Accredited Flag	2152	2018	
Other Primary Tumors	2200	1995 - 2020	
Last Name	2230	1995 - present	
Birth Surname	2232	2021 - present	
First Name	2240	1995 - present	
Middle Name	2250	1995 - present	
Name--Suffix	2270	2022 - present	
Patient Name Alias	2280	1995 - 2002 2006 - present	
Medical Record #	2300	1995 - present	
Medicare Beneficiary Identifier	2315	2021 - present	
Social Security Number	2320	1995 - present	
Address at Dx Street Address	2330	1995 - present	
Address at Dx Supplemental	2335	2006 - present	
Current Address Number and Street	2350	2022 - present	
Current Address Supplemental	2355	2022 - present	
Telephone	2360	2022 - present	
Maiden Name	2390	1995 - 2020	
Facility Referred From	2410	2001 - 2010	
Facility Referred To	2420	2001 - 2010	
Physician Managing	2460	2006 - 2010	
Physician Follow Up	2470	2006 - present	
Final DX Primary Site and Laterality	2580	1995 - present	

Data Item	NAACCR Item Number	Collection Dates	
Final DX Morph/Beh/Grade	2590	1995 - present	
RX Text Surgery	2610	2004 - present	
RX Text - Chemotherapy	2640	2004 - present	
RX Text - Hormone	2650	2004 - present	
RX Text - Immunotherapy	2660	2004 - present	
RX Text - Other	2670	2004 - present	
Other Pertinent Information	2680	1995 - present	
CS Tumor Size 2004 and forward	2800	2004 - 2015	
CS Extension	2810	2004 - 2015	
CS Tumor Size/EXT Eval	2820	2008 - 2015	
CS Lymph Nodes	2830	2004 - 2015	
CS Lymph Nodes Eval	2840	2011 - 2015	
CS Mets at DX	2850	2004 - 2015	
CS Mets Eval	2860	2011 - 2015	
CS Site Specific Factor 7 NPCR required only	2861	2011 - 2015	
CS Site Specific Factor 8 NPCR required only	2862	2010 - 2017	
CS Site Specific Factor 9 NPCR required only	2863	2010 - 2017	
CS Site Specific Factor 10 NPCR required only	2864	2010 - 2017	
CS Site Specific Factor 11 NPCR required only	2865	2010 - 2017	
CS Site Specific Factor 12 NPCR required only	2866	2010 - 2015	
CS Site Specific Factor 13 NPCR required only	2867	2010 - 2017	
CS Site Specific Factor 14 NPCR required only	2868	2010 - 2017	
CS Site Specific Factor 15 NPCR required only	2869	2011 - 2017	
CS Site Specific Factor 16 NPCR required only	2870	2011 - 2017	
CS Site Specific Factor 17 NPCR required only	2871	2011 - 2015	
CS Site Specific Factor 25 NPCR required only	2879	2010 - 2017	
CS Site Specific Factor 1 NPCR required only	2880	2004 - 2017	
CS Site Specific Factor 2 NPCR required only	2890	2010 - 2017	
CS Site Specific Factor 3 NPCR required only	2900	2004 - 2015	
CS Site Specific Factor 4 NPCR required only	2910	2011 - 2015	
CS Site Specific Factor 5 NPCR required only	2920	2011 - 2017	
CS Site Specific Factor 6 NPCR required only	2930	2011 - 2017	

Data Item	NAACCR Item Number	Collection Dates	
Comorbidity/Secondary Diagnosis #1	3110	2011 - 2017	
Comorbidity/Secondary Diagnosis #2	3120	2011 - 2017	
Comorbidity/Secondary Diagnosis #3	3130	2011 - 2017	
Comorbidity/Secondary Diagnosis #4	3140	2011 - 2017	
Comorbidity/Secondary Diagnosis #5	3150	2011 - 2017	
Comorbidity/Secondary Diagnosis #6	3160	2011 - 2017	
Comorbidity/Secondary Diagnosis #7	3161	2011 - 2017	
Comorbidity/Secondary Diagnosis #8	3162	2011 - 2017	
Comorbidity/Secondary Diagnosis #9	3163	2011 - 2017	
Comorbidity/Secondary Diagnosis #10	3164	2011 - 2017	
RX Date Mst Defn Srg	3170	2015 - present	
RX Date Mst Defn Srg Flag	3171	2015 - 2021	
RX Date - Systemic	3230	2004 – 2010 2022 -present	CoC
RX Summary Transplant/Endocrine	3250	2003 - present	
SEER Site Specific Factor 1	3700	2022 - present	
Secondary Diagnosis 1	3780	2023	
Secondary Diagnosis 2	3782	2023	
Secondary Diagnosis 3	3784	2023	
Secondary Diagnosis 4	3786	2023	
Secondary Diagnosis 5	3788	2023	
Secondary Diagnosis 6	3790	2023	
Secondary Diagnosis 7	3792	2023	
Secondary Diagnosis 8	3794	2023	
Secondary Diagnosis 9	3796	2023	
Secondary Diagnosis 10	3798	2023	
Schema ID	3800		Derived
Chromosome 1p: Loss of Heterozygosity (LOH)	3801	2022 - present	
Chromosome 19q: Loss of Heterozygosity (LOH)	3802	2022 - present	
Adenoid Cystic Basaloid Pattern	3803	2022 - present	
Adenopathy	3804	2022 - present	
AFP Post-Orchiectomy Lab Value	3805	2022 - present	CoC
AFP Post-Orchiectomy Range	3806	2022 - present	
AFP Pre-Orchiectomy Lab Value	3807	2022 - present	CoC
AFP Pre-Orchiectomy Range	3808	2022 - present	
AFP Pretreatment Interpretation	3809	2022 - present	CoC
AFP Pretreatment Lab Value	3810	2022 - present	CoC

Data Item	NAACCR Item Number	Collection Dates	
Anemia	3811	2022 - present	
B symptoms	3812	2022 - present	
Bilirubin Pretreatment Total Lab Value	3813	2022 - present	CoC
Bilirubin Pretreatment Unit of Measure	3814	2022 - present	CoC
Bone Invasion	3815	2022 - present	
Brain Molecular Markers	3816	2018 – present	
Breslow Tumor Thickness	3817	2018 – present	
CA-125 Pretreatment Interpretation	3818	2022 - present	
CEA Pretreatment Interpretation	3819	2022 - present	
CEA Pretreatment Lab Value	3820	2022 - present	
Chromosome 3 Status	3821	2022 - present	CoC
Chromosome 8q Status	3822	2022 - present	CoC
Circumferential Resection Margin (CRM)	3823	2022 - present	
Creatinine Pretreatment Lab Value	3824	2022 - present	CoC
Creatinine Pretreatment Unit of Measure	3825	2022 - present	CoC
Estrogen Receptor Percent Positive or Range	3826	2022 - present	CoC
Estrogen Receptor Summary	3827	2018 – present	
Esophagus and EGJ Tumor Epicenter	3829	2022 - present	
Extranodal Extension Clin (non-Head and Neck)	3830	2022 - present	CoC
Extranodal Extension Head and Neck Clinical	3831	2022 - present	CoC
Extranodal Extension Head and Neck Pathological	3832	2022 - present	
Extranodal Extension Path (non-Head and Neck)	3833	2022 - present	CoC
Extravascular Matrix Patterns	3834	2022 - present	CoC
Fibrosis Score	3835	2018 – present	
FIGO Stage	3836	2022 - present	
Gestational Trophoblastic Prognostic Scoring Index	3837	2022 - present	
Gleason Patterns Clinical	3838	2021 - present	
Gleason Patterns Pathological	3839	2021 - present	
Gleason Score Clinical	3840	2021 - present	
Gleason Score Pathological	3841	2021 - present	
Gleason Tertiary Pattern	3842	2021 - present	
Grade Clinical	3843	2018 – present	
Grade Pathological	3844	2018 - present	
Grade Post Therapy Path (yp)	3845	2021 - present	
hCG Post-Orchiectomy Lab Value	3846	2022 - present	CoC

Data Item	NAACCR Item Number	Collection Dates	
hCG Post-Orchiectomy Range	3847	2022 - present	
hCG Pre-Orchiectomy Lab Value	3848	2022 - present	CoC
hCG Pre-Orchiectomy Range	3849	2022 - present	
HER2 Overall Summary	3855	2018 – present	
Heritable Trait	3856	2022 - present	
High Risk Cytogenetics	3857	2022 - present	
High Risk Histologic Features	3858	2022 - present	
HIV Status	3859	2022 - present	
International Normalized Ratio Prothrombin Time	3860	2022 - present	CoC
Ipsilateral Adrenal Gland Involvement	3861	2022 - present	
JAK2	3862	2022 - present	
Ki-67	3863	2022 - present	CoC
Invasion Beyond Capsule	3864	2022 - present	
KIT Gene Immunohistochemistry	3865	2022 - present	CoC
KRAS	3866	2022 - present	
LDH Post-Orchiectomy Range	3867	2022 - present	
LDH Pre-Orchiectomy Range	3868	2022 - present	
LDH Level	3869	2022 - present	
LDH Upper Limits of Normal	3870	2022 - present	CoC
LN Assessment Method Femoral-Inguinal	3871	2022 - present	CoC
LN Assessment Method Para-Aortic	3872	2022 - present	CoC
LN Assessment Method Pelvic	3873	2022 - present	CoC
LN Distant Assessment Method	3874	2022 - present	CoC
LN Distant: Mediastinal, Scalene	3875	2022 - present	CoC
LN Head and Neck Levels I-III	3876	2022 - present	
LN Head and Neck Levels IV-V	3877	2022 - present	
LN Head and Neck Levels VI-VII	3878	2022 - present	
LN Head and Neck Other	3879	2022 - present	
LN Isolated Tumor Cells (ITC)	3880	2022 - present	
LN Laterality	3881	2022 - present	
LN Positive Axillary Level I-II	3882	2022 - present	
LN Size	3883	2022 - present	
LN Status Femoral-Inguinal, Para-Aortic, Pelvic	3884	2022	
Lymphocytosis	3885	2022 - present	
Major Vein Involvement	3886	2022 - present	
Measured Basal Diameter	3887	2022 - present	
Measured Thickness	3888	2022 - present	

Data Item	NAACCR Item Number	Collection Dates	
Methylation of O6-Methylguanine-Methyltransferase	3889	2022 - present	
Microsatellite Instability (MSI)	3890	2018 - present	
Microvascular Density	3891	2022 - present	CoC
Mitotic Count Uveal Melanoma	3892	2022 - present	CoC
Mitotic Rate Melanoma	3893	2022 - present	
Multigene Signature Method	3894	2022 - present	
Multigene Signature Results	3895	2022 - present	
NCCN International Prognostic Index (IPI)	3896	2022 - present	
Number of Cores Examined	3897	2022 - present	
Number of Cores Positive	3898	2022 - present	
Number of Examined Para-Aortic Node	3899	2022 - present	CoC
Number of Examined Pelvic Nodes	3900	2022 - present	CoC
Number of Positive Para-Aortic Nodes	3901	2022 - present	CoC
Number of Positive Pelvic Nodes	3902	2022 - present	CoC
Oncotype Dx Recurrence Score-DCIS	3903	2022 - present	CoC
Oncotype Dx Recurrence Score-Invasive	3904	2022 - present	
Oncotype Dx Risk Level-DCIS	3905	2022 - present	CoC
Oncotype Dx Risk Level-Invasive	3906	2022 - present	CoC
Organomegaly	3907	2022 - present	
Percent Necrosis Post Neoadjuvant	3908	2022 - present	CoC
Perineural Invasion	3909	2022 - present	
Peripheral Blood Involvement	3910	2022 - present	
Peritoneal Cytology	3911	2022 - present	
Pleural Effusion	3913	2022 - present	
Progesterone Receptor Percent Positive or Range	3914	2022 - present	CoC
Progesterone Receptor Summary	3915	2018 – present	
Profound Immune Suppression	3918	2022 - present	
EOD Prostate Pathologic Extension	3919	2022 - present	
PSA (Prostatic Specific Antigen) Lab Value	3920	2018 – present	
Residual Tumor Volume Post Cytoreduction	3921	2022 - present	
Response to Neoadjuvant Therapy	3922	2022 - present	CoC
S Category Clinical	3923	2022 - present	
S Category Pathological	3924	2022 - present	
Sarcomatoid Features	3925	2022 - present	
Schema Discriminator 1	3926	2018 - present	
Schema Discriminator 2	3927	2018 - present	

Data Item	NAACCR Item Number	Collection Dates	
Schema Discriminator 3	3928	2022 - present	
Separate Tumor Nodules	3929	2022 - present	
Serum Albumin Pretreatment Level	3930	2022 - present	
Serum Beta-2 Microglobulin Pretreatment Level	3931	2022 - present	
LDH Lab Value	3932	2018 – present	
Tumor Deposits	3934	2022 - present	
Ulceration	3936	2022 - present	
Visceral and Parietal Pleural Invasion	3937	2022 - present	
ALK Rearrangement	3938	2022 - present	
EGFR Mutational Analysis	3939	2022 - present	
BRAF Mutational Analysis	3940	2022 - present	
NRAS Mutational Analysis	3941	2022 - present	
CA 19-9 PreTX Lab Value	3942	2022 - present	
NCDB--SARSCoV2--Pos	3944	2022 - present	CoC
Macroscopic Evaluation of the Mesorectum	3950	2022 - present	CoC
p16	3956	2022 - present	
LN Status Pelvic	3957	2022 - present	CoC
LN Status Para-Aortic	3958	2022 - present	CoC
LN Status Femoral-Inguinal	3959	2022 - present	CoC
Histologic Subtype	3960	2022	
Clinical Margin Width	3961	2023	
RX Text - Radiation	2620, 2630	2004 - present	
Height	Non - NAACCR 9960	2011 - 2020	
Weight	Non - NAACCR 9961	2011 - 2020	
Source Comorbidity/Secondary Diagnosis	Non-NAACCR 9970	2011 - 2017	

TCR does not allow blanks for the following items:

*Date of Admission/First Contact, NAACCR #580

*Date of Date of Birth, NAACCR #240

